Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupMEDGF +90.68%71 EV-to-OCF is 19.13 as of Aug. 31, 2026, which is 44% below its 10-year median of 34.07. GuruFocus rates MEDGF with a GF Score™ of 71/100 and a GF Value™ of $91.08 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Medacta Group ranks worse than 72.97% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Medacta Group's Enterprise Value is $3,395.8 Mil.
Medacta Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $177.5 Mil. Therefore, Medacta Group's EV-to-OCF for today is 19.13.
The historical rank and industry rank for Medacta Group's EV-to-OCF or its related term are showing as below:
MEDGF'
s EV-to-OCF Range Over the Past 10 Years
Min: 19.12 Med: 34.07 Max: 52.57
Current: 19.12
During the past 11 years, the highest EV-to-OCF of Medacta Group was 52.57. The lowest was 19.12. And the median was 34.07.
MEDGF's EV-to-OCF is ranked worse than 72.97% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 7.91
vs MEDGF: 19.12
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medacta Group's PE Ratio (TTM) for today is calculated as:
Medacta Group's share price for today is $160.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medacta Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $5.545.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medacta Group EV-to-OCF Related Terms
Medacta Group EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Medacta Group's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medacta Group's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Medacta Group's EV-to-OCF falls into.
Medacta Group's current Enterprise Value is $3,395.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medacta Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $177.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (MEDGF) has a EV-to-OCF of 19.13 as of Aug. 31, 2026. This is 44% below median its historical median of 34.07. Over the past decade, Medacta Group's EV-to-OCF has ranged from 19.12 to 52.57. According to the industry distribution chart, Medacta Group ranks #621 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 73%.
Is Medacta Group's EV-to-OCF too high?
Medacta Group's current EV-to-OCF of 19.13 is 44% below median its 10-year median of 34.07. Over the past 10 years, this metric has ranged from a low of 19.12 to a high of 52.57. The Medical Devices & Instruments industry median EV-to-OCF is 7.91. Medacta Group's value of 19.13 is 141.8% above this industry median. Based on the distribution chart, Medacta Group ranks #621 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medacta Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #621 out of 851 companies for EV-to-OCF. This places Medacta Group in the lower half of its industry. The industry median EV-to-OCF is 7.91. Medacta Group's value of 19.13 is 141.8% above this benchmark. Historically, Medacta Group's own EV-to-OCF has ranged from 19.12 to 52.57 over the past decade. While the company's 10-year median is 34.07 vs. the industry median of 7.91, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.91, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current EV-to-OCF of 19.13 is 141.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current EV-to-OCF is 19.13, which is 44% below median its own 10-year median of 34.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (MEDGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $91.08, compared to a current price of $160.00 — trading 75.7% above its estimated fair value. The current EV-to-OCF is 19.13, which is 44% below median its 10-year median of 34.07 and 141.8% above the Medical Devices & Instruments industry median of 7.91. Medacta Group's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Medacta Group (MEDGF), the current EV-to-OCF is 19.13 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (MEDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be overvalued.
The current stock price of $160.00 is trading 75.7% above its estimated GF Value™ of $91.08.
GuruFocus considers Medacta Group to be Significantly Overvalued.
Key valuation signals for MEDGF:
EV-to-OCF: 19.13 (44% below median its 10-year median of 34.07)
GF Value™: $91.08 vs. price of $160.00 (75.7% above fair value)
Industry Position: 141.8% above the Medical Devices & Instruments median (#621 of 851)
No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
71GF Score
Get the complete analysis for MEDGF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDGF has been successfully added to your 
